Innovation

Contributed by: AstraZeneca

Tags

Liver Cancer Treatment

Innovation

More Like This

ASTRAZENECA RECEIVES TWO POSITIVE NICE RECOMMENDATIONS FOR LUNG CANCER PATIENTS ACROSS ENGLAND AND WALES

ASTRAZENECA’S IMFINZI (DURVALUMAB) RECOMMENDED BY NICE FOLLOWING MHRA APPROVAL AS FIRST IMMUNOTHERAPY IN COMBINATION WITH PERIOPERATIVE CHEMOTHERAPY IN RESECTABLE GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION CANCER

IMFINZI (DURVALUMAB) IN COMBINATION WITH CHEMOTHERAPY RECEIVES POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE FOR PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER

PATIENTS ACROSS ENGLAND AND WALES GAIN ACCESS TO NEW TREATMENT OPTION FOR MANTLE CELL LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA FOLLOWING POSITIVE NICE DECISIONS

PR Newswire associated0

EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

PATIENTS IN SCOTLAND GAIN ACCESS TO CANCER TREATMENTS FOR LUNG CANCER AND CHRONIC LYMPHOCYTIC LEUKAEMIA FOLLOWING SMC DECISIONS

PR Newswire associated0

PharmaMar presents at ASCO that the Zepzelca®(lurbinectedin) and atezolizumab (Tecentriq®) combination significantly improves survival as first-line maintenance therapy for extensive-stage small cell lung cancer

Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer